Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 1/20 | 0.38 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.38 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.38 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.38 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 9/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877858 | 0.87 | UCHL1 (0.37) | EEDRBBP4SUZ12EZH2AEBP2 | |
| SCHEMBL4873785 | 0.79 | HRH4 (0.54) | PIK3CAPIK3R1NR1H2NR1H3UCHL1 | |
| SCHEMBL4876826 | 0.78 | HRH4 (0.37) | JAK3 | |
| SCHEMBL4877386 | 0.77 | HRH4 (0.52) | RETPIK3CAPIK3R1NR1H2NR1H3 | |
| SCHEMBL606300 | 0.76 | HRH4 (0.49) | — | |
| SCHEMBL4868988 | 0.76 | HRH4 (0.39) | JAK3 | |
| SCHEMBL15727044 | 0.70 | HRH4 (0.42) | GPR119RETNR1H2NR1H3UCHL1 | |
| SCHEMBL4877657 | 0.70 | UCHL1 (0.42) | GPR119NR1H2NR1H3UCHL1USP30 | |
| SCHEMBL4876139 | 0.69 | HRH4 (0.46) | PIK3CAPIK3R1 | |
| SCHEMBL16931878 | 0.69 | NR1H2 (0.41) | GPR119RETPIK3CANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | ABBVIE INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188452-A1 | Macrocyclic Benzofused Pyrimidine Derivatives | DPYD, TYMS, UMPS | EED 620/4885RBBP4 622/4885SUZ12 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.